BRCA1 oncogenic variants

About

Gene context: BRCA1

Biomarker Type: Somatic Variant

Present: True

Chromosome: 17

Requires Oncogenic: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
EMA (1) FDA (2) HSE (2) BRCA1 oncogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (2) HSE (2) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Rucaparib
EMA (1) HSE (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone